| Address: | 4-10 Inman Rd, Dee Why NSW 2099, Australia |
|---|---|
| Postal code: | 2099 |
| Phone: | 1800 233 950 |
| Website: | http://mabthera.com.au/ |
There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about MabThera, use the form below and your opinion, advice or comment will appear in this space.
As MabThera SC is given to you under the supervision of your doctor, it is very unlikely that you will receive too much. ... 1800 233 950. Please check with your ...
This leaflet answers some common questions about MabThera SC for subcutaneous (under the skin) injection. It does not contain all the available information. It does not take the place of talking ...
Pharmacists are advised to contact their usual wholesaler, or an alternative wholesaler, in the event that they cannot secure supply. Pharmacists may also contact Apotex Customer Services directly on 1800 276 839 or by email at: customer.service.aus@apotex.com to identify an alternative wholesaler. Patients. Consumer Medicine Information (CMI)
MabThera SC may cause a reduction in blood pressure at the beginning of treatment. Because MabThera SC may cause a temporary drop in your blood pressure, your doctor may advise you to temporarily stop taking your blood pressure medicine before you are given MabThera SC.
Roche Products Pty Limited Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.
Home » Store » Roche's MabThera Recommended by NICE When TNF Inhibitors Fail. Roche's MabThera Recommended by NICE When TNF Inhibitors Fail. Price: $20.00
ACTEMRA VIAL 400MG/20ML 1 * temporarily out of stock. ... Medical enquiries: 1800 233 950. Please check with your pharmacist for the latest Consumer Medicine Information.
Hyperuricaemia (Grade 3/4) occurred in 143/950 (15%) patients, with the majority post-infusion on days 1 and/or 15. It was not associated with any clinical symptoms, and none of these patients developed evidence of renal disease. Increases in serum uric acid are often associated with the catabolism of DNA.
Attachment 1: Product information for AusPAR MabThera Rituximab Roche Products Pty Ltd PM-2014-04709-1-4 Final 9 February 2017. This Product Information was approved at the time this AusPAR was published.
233 4/14/2014. 234 11/9/2016. 235 10/18/2016. 236 ... 950 10/5/1990. 951 11/19/1987. 952 10/15/2014. 953 ... 1800 8/20/2010. 1801 4/7/2005. 1802 10/29/2015. 1803 4/6 ...